Immunogenicity and reactogenicity of a bicomponent and a tricomponent acellular pertussis-diphtheria-tetanus (DTaP) Vaccine in primary immunization and as second year booster: A double-blind, randomized trial

International Journal of Infectious Diseases

Volumn 1, Issue 1, 1996, Pages 6-13

  Schmitt, Heinz J ^a,c   Müschenborn, Simone ^a   Wagner, Sabine ^a   Knuf, Markus ^a   Bock, Hans L ^b   Bogaerts, Hugues ^b   Clemens, Ralf ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SmithtKline Beecham Biologicals   (Belgium)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

Acellular; Hemagglutinin; Pertactin; Pertussis; Toxoid

Indexed keywords

EID: 0002328091     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(96)90070-3     Document Type: Article

References (40)

1. Muller AS, Leeuwenburg J, Pratt DS. Pertussis: epidemiology and control. Bull World Health Organ 1986; 64:321-331.
2. Harden GF, Sato PA, Wright PF, Henderson RH. Progress in worldwide control and elimination of disease through immunization. J Pediatr 1989; 144:520-327.
3. Frenkel LD. Pertussis immunization. Pediatr Ann 1986; 15:452-454.
4. Wirsing von König CH. Keuchhusten: Mikrobiologie, Epidemiologie, Prophylaxe. Die gelben Hefte 1993; 33:80-86.
5. Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 1984; 14:1-78.
6. Romanus V, Jonsell R, Bergquist S-O. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987; 6:364-371.
7. Kimura M, Kuno-Sakai H. Developments in pertussis immunisation in Japan. Lancet 1990; 336:30-32.
8. Stehr K, Heininger U. Aktueller Stand der Keuchhustenschutzimpfung. Pädiatr Praxis 1991; 42:391-402.
9. Miller E. Vurdien JE, White JM. The epidemiology of pertussis in England and Wales. Commun Dis Rep CDR Rev 1992; 2:132-154.
10. Finger H, Wirsing von König CH, Tacken A, Wassilak SGF. The epidemiological situation of pertussis in the Federal Republic of Germany. Develop Biol Stand 1991; 73:343-355.
11. Noble GR, Bernier RH, Esber EC, et al. Acellular and wholecell pertussis vaccines in Japan. Report of a visit by US scientists. JAMA 1987; 257:1351-1356
12. Edwards KM, Lawrence E, Wright PF. Diphtheria, tetanus, and pertussis vaccine: a comparison of the immune response and adverse reactions to conventional and acellular pertussis components. Am J Dis Child 1986; 140:867-871.
13. Anderson EL, Belshe RB, Bartram J, et al. Clinical and serologic responses to acellular pertussis vaccine in infants and young children. Am J Dis Child 1987; 141:949-953.
14. Morgan CM, Blumberg DA, Cherry JD, et al. Comparison of acellular and whole-cell pertussis-component DTP vaccines. Am J Dis Child 1990; 144:41-45.
15. Pichichero ME, Francis AB, Marsocci SM, et al. Safety and inrmunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized -with acellular or -whole-cell pertussis vaccine as infants. Pediatrics 1993; 91:756-760.
16. Bernstein DI, Smith VE, Schiff GM, Rathfon HM, Boscia JA. Comparison of acellular pertussis vaccine with whole-cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age. Pediatr Infect Dis J 1993; 12:131-135.
17. Bernstein HH, Rothstein EP, Pennridge Pediatric Associates, et al. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants. Pediatrics 1994; 93:656-659.
18. Vanura H, Just M, Ambrosch F, et al. Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 pg of FHA and either 25 or 8 μg of PT with response to whole-cell pertussis DTP vaccine. Vaccine 1994; 12:210-214.
19. Wiersbitzky S, Bock HL, Bruns R, et al. Verträglichkeit und Immunogenität einer 3-Komponenten-azellulären-Pertussis-Vakzine (DTPa) im Vergleich zur klassischen DTPg- Vakzine. Monatsschr Kinderheilkd 1996; 144 (in press).
20. Ruuskanen O, Noel A. Putto-Laurila A, et al. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults. Vaccine 1991; 9:117-121.
21. Kanra G, Ceyhan M, Vandevoorde D, Bogaerts H. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children. Eur J Pediatr 1993; 152-478-483.
22. Camargo ME, Silveira L, Furuta JA, Oliveira EPT, Germak OA. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 1984; 20:772-774.
23. Melville-Smith M, Seagroatt V, Watkins J. A comparison on enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983; 11:137-144.
24. Melville-Smith M, Balfour A. Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin, neutralisation test. J Med Microbiol 1988; 25:279-283.
25. Pichichero ME, Christy C, Decker MD, et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics 1995; 96(Suppl): 588-592.
26. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96(Suppl):548-557.
27. Cherry JD. Acellular pertussis vaccines - a solution to the pertussis problem. J Infect Dis 1993; 168:21-24.
28. Wirsing von König CH, Finger H. Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection Eur J Clin Microbiol Infect Dis 1994; 13:455-458.
29. Sato H, Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin, with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun 1984; 46:415-421.
30. He Q, Viljanen MK, Öander RM. Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in school children. J Infect Dis 1994; 170:705-708.
31. Shahin RD, Brennan MJ, Li ZM, Meade BD, Manclark CR. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med 1990; 171:63-73.
32. Thomas MG, Redhead K, Lambert HP Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination. J Infect Dis 1989; 159:211-218.
33. Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 1994; 93:37-43.
34. Weirsbitzky S, Bock HL, Bogaerts H, et al. Comparison of reactogenicity and immunogenicity of a tricomponent acellular pertussis vaccine with a conventional whole-cell vaccine for primary and booster immunisation in infants. A prospective randomised double-blind study in Germany. Eur J Pediatr 1996 (Submitted).
35. Schmitt H-J, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41.
36. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-348.
37. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine N Engl J Med 1996; 334:349-355.
38. Storsaeter J, Olin P Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine 1992; 10:142-144.
39. Mortimer EA, Kimura M, Cherry JD, et al. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Child 1990; 144:899-904.
40. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996; 334:391-392.